XY-221 is a BRD4 Second Bromodomain (BD2)-Selective Inhibitor. XY-221 demonstrated potent binding affinity for BRD4 BD2 (IC50 = 5.8 nM), along with high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9−32-fold over BRD2/3/T BD2). The BRD4 BD2 selectivity of XY-221 was further confirmed by the BLI assay, showing 66−144-fold selectivity over other BET BD2 domains. 16o exhibited good liver microsomal stability (T1/2 > 120 min) and pharmacokinetic properties (F = 13.1%).
MedKoo Cat#: 128192
Name: XY221
CAS#: N/A
Chemical Formula: C32H34FN3O5
Exact Mass: 559.2482
Molecular Weight: 559.64
Elemental Analysis: C, 68.68; H, 6.12; F, 3.39; N, 7.51; O, 14.29
The following data is based on the product molecular weight 559.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
